{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Thrombotic+Disease&page=5",
    "query": {
      "condition": "Thrombotic Disease",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 232,
    "total_pages": 24,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Thrombotic+Disease&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Thrombotic+Disease&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T06:26:42.493Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02422875",
      "title": "Comparative Autoantibody and Immunologic Cell Marker Study",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Autoimmune Diseases",
        "Lupus Erythematosus, Systemic",
        "Communicable Diseases"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2500,
      "start_date": "2012-08",
      "completion_date": "2028-05",
      "has_results": false,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-23T06:26:42.493Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02422875"
    },
    {
      "nct_id": "NCT05757570",
      "title": "An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias (RUBY-4)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Thrombocytopenic Purpura",
        "Immune Thrombocytopenia",
        "Warm Autoimmune Hemolytic Anemia",
        "Cold Agglutinin Disease"
      ],
      "interventions": [
        {
          "name": "Povetacicept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alpine Immune Sciences Inc, A Subsidiary of Vertex",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2023-07-03",
      "completion_date": "2026-08-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-10-23T06:26:42.493Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Cooper City, Florida + 11 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Cooper City",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05757570"
    },
    {
      "nct_id": "NCT01522183",
      "title": "Atypical Hemolytic-Uremic Syndrome (aHUS) Registry",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Atypical Hemolytic-Uremic Syndrome"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 3000,
      "start_date": "2013-03-18",
      "completion_date": "2031-01-01",
      "has_results": false,
      "last_update_posted_date": "2025-09-16",
      "last_synced_at": "2026-10-23T06:26:42.493Z",
      "location_count": 9,
      "location_summary": "Aurora, Colorado • Washington D.C., District of Columbia • Gainesville, Florida + 6 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01522183"
    },
    {
      "nct_id": "NCT03275740",
      "title": "A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy",
        "Primary Immune Thrombocytopenia",
        "Polyradiculoneuropathy, Chronic Inflammatory Demyelinating"
      ],
      "interventions": [
        {
          "name": "PF-06755347 intravenous healthy participant",
          "type": "DRUG"
        },
        {
          "name": "Placebo intravenous healthy participant",
          "type": "DRUG"
        },
        {
          "name": "PF-06755347 subcutaneous healthy participant",
          "type": "DRUG"
        },
        {
          "name": "Placebo subcutaneous healthy participant",
          "type": "DRUG"
        },
        {
          "name": "PF-06755347 subcutaneous ITP",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 58,
      "start_date": "2017-07-17",
      "completion_date": "2023-01-06",
      "has_results": true,
      "last_update_posted_date": "2024-07-05",
      "last_synced_at": "2026-10-23T06:26:42.493Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03275740"
    },
    {
      "nct_id": "NCT00844844",
      "title": "Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atypical Hemolytic Uremic Syndrome"
      ],
      "interventions": [
        {
          "name": "Eculizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 1,
      "start_date": "2009-05",
      "completion_date": "2013-07",
      "has_results": true,
      "last_update_posted_date": "2015-07-23",
      "last_synced_at": "2026-10-23T06:26:42.493Z",
      "location_count": 6,
      "location_summary": "Atlanta, Georgia • Fort Wayne, Indiana • New York, New York + 2 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Grapevine",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00844844"
    },
    {
      "nct_id": "NCT00953771",
      "title": "Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Thrombotic Thrombocytopenic Purpura"
      ],
      "interventions": [
        {
          "name": "Danazol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2008-10",
      "completion_date": "2015-11-19",
      "has_results": true,
      "last_update_posted_date": "2024-07-23",
      "last_synced_at": "2026-10-23T06:26:42.493Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00953771"
    },
    {
      "nct_id": "NCT04200456",
      "title": "A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Immune Thrombocytopenia"
      ],
      "interventions": [
        {
          "name": "Rozanolixizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "UCB Biopharma SRL",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2020-01-31",
      "completion_date": "2022-04-27",
      "has_results": true,
      "last_update_posted_date": "2025-03-18",
      "last_synced_at": "2026-10-23T06:26:42.493Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04200456"
    },
    {
      "nct_id": "NCT07700238",
      "title": "A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Immune Thrombocytopenia"
      ],
      "interventions": [
        {
          "name": "Romiplostim",
          "type": "DRUG"
        },
        {
          "name": "Predniso(lo)ne",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 126,
      "start_date": "2026-08-21",
      "completion_date": "2029-10-14",
      "has_results": false,
      "last_update_posted_date": "2026-09-17",
      "last_synced_at": "2026-10-23T06:26:42.493Z",
      "location_count": 3,
      "location_summary": "Long Beach, California • Peoria, Illinois • Fredericksburg, Virginia",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Fredericksburg",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07700238"
    },
    {
      "nct_id": "NCT02553317",
      "title": "Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acquired Thrombotic Thrombocytopenic Purpura"
      ],
      "interventions": [
        {
          "name": "Caplacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Ablynx, a Sanofi company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 145,
      "start_date": "2015-11",
      "completion_date": "2017-08",
      "has_results": true,
      "last_update_posted_date": "2023-04-05",
      "last_synced_at": "2026-10-23T06:26:42.493Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02553317"
    },
    {
      "nct_id": "NCT07732361",
      "title": "A Study Using Real-world Data to Examine Outcomes in Children and Adults Who Develop a Blood Clotting Disorder Called Thrombotic Microangiopathy (TMA) After Undergoing a Hematopoietic Stem Cell Transplant (HSCT).",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Thrombotic Microangiopathy",
        "Hematopoietic Stem Cell Transplant"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Weeks",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "4 Weeks and older"
      },
      "enrollment_count": 307,
      "start_date": "2025-01-22",
      "completion_date": "2026-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-28",
      "last_synced_at": "2026-10-23T06:26:42.493Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Akron, Ohio • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Akron",
          "state": "Ohio"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07732361"
    }
  ]
}